Importantly, the knockdown of BACH1 abolished the phenotypes elicited by PLK1 in both human and melanoma cells, with reduced glycolysis, increased OXPHOS, inhibited metastasis, and resensitization to Vemurafenib treatment. The gene discussed is PLK1; the disease is melanoma.